Abstract: AZD5423 is a novel, inhaled, selective glucocorticoid receptor modulator (SGRM), which in an allergen challenge model in asthma patients improved lung function and airway hyper-reactivity. In the current trial, AZD5423 was for the first time tested in patients with chronic obstructive pulmonary disease (COPD). In this double-blind, randomized and parallel group study, we examined airway and systemic effects of two doses of AZD5423, inhaled via Turbuhaler for 12 weeks, in 353 symptomatic patients with COPD (average pre-bronchodilator forced expiratory volume in one-second (FEV1) at screening was 50-52% of predicted normal). Pre-bronchodilator FEV1 was primary variable, with other lung function parameters plus symptoms and 24-hr plasma cortisol being secondary variables. Plasma concentrations of AZD5423 were also measured. Effects were compared against placebo and a reference glucocorticoid receptor agonist control. Neither AZD5423, at doses which have shown to be efficacious in allergen-induced asthma, nor the reference control, at double the approved dose, had any clinically meaningful effect in the patient population studied in regard to lung function or markers of inflammation. Both GR modulators were well tolerated and did suppress 24-hr cortisol. This study suggests that the selected population of patients with COPD does not respond to treatment with AZD5423 as regards lung function, while showing the expected systemic effects. It cannot be ruled out that a favourable lung function response of AZD5423 can be evoked using another experimental setting and/or within a different population of patients with COPD.
Current treatment guidelines in chronic obstructive pulmonary disease (COPD) recommend inhaled corticosteroids (ICS) in combination with inhaled long-acting b 2 -adrenoceptor agonists (LABA) to treat patients with severe airflow limitation and/or COPD with a history of exacerbations [1] . Arguably, the effect of anti-inflammatory ICS in COPD remains controversial: To date, a small number of trials have shown ICS to slow down the accelerated decline in lung function typical of COPD [2, 3] , but systematic reviews on the use of ICS in COPD have failed to show this to be a true and reproducible effect [4, 5] . Systematic reviews demonstrate, however, a clear beneficial effect on exacerbation risk and quality of life [4, 6] . Also, many large and well-controlled trials of long treatment duration have provided compelling evidence of improved lung function, reduction of symptoms and exacerbation frequency, as well as improved health-related quality of life when ICS are added to bronchodilator treatment [5, [7] [8] [9] . Some trials -generally of smaller size or in particular COPD patient groups -have, however, not been able to provide evidence of benefit of ICS in COPD [10, 11] . In terms of risk, long-term treatment with ICS may reduce bone mineral density, increase the risk of fractures and increase the liability for oral candidiasis, bruising and cataracts [12, 13] . In addition, the risk of pneumonia may be increased in patients with COPD after ICS treatment [14] , although this finding appears to be confined to certain ICS compounds rather than the drug class [15] . Clearly, there is a medical need for an improved anti-inflammatory treatment with a more selective mode of action in COPD.
Recently, two of a new generation of more selective inhaled glucocorticoid receptor (GR) agonists have been clinically tested: (i) The partial steroidal agonist GW 870086, where clinical effect could not be demonstrated in mild-to-moderate asthma [16] , and (ii) the experimental, non-steroidal, selective GR modulator (SGRM) AZD5423, which is described in the present paper. The affinity of AZD5423 to the GR is high (IC50 in a radioligand human GR receptor assay was 0.9 nmol/L) [17] , and the selectivity towards other steroid hormone receptors is >900-fold. AZD5423 modulates the GR in a novel way compared with conventional glucocorticosteroids [18, 19] . It has demonstrated beneficial effects in pre-clinical inflammation models and reduced allergen-induced inflammatory responses in patients with mild allergic asthma [20] . Pre-clinically, AZD5423 displays similar qualitative safety findings as those of conventional GR ligands (e.g. cortical atrophy, decreased body-weight and effects on carbohydrate and protein metabolism), but with margins towards predicted safe clinical doses which may be greater than conventional ICS. Hence, it is suggested that inhaled AZD5423 will show a better benefit risk ratio than conventional glucocorticoids currently being used for the treatment of asthma and COPD.
Here, we report the first study with AZD5423 in patients with COPD. In this multi-centre, double-blind, randomized, parallel group study [21] , AZD5423 at two different doses was compared with placebo and a high dose of inhaled budesonide.
Methods
Individuals. Patients clinically diagnosed since at least 1 year with COPD according to the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline were eligible if they were >40 years, had an FEV1 (forced expiratory volume in 1 sec.) of 40-80% of predicted normal pre-bronchodilator, a ratio of FEV1 to forced vital capacity (FVC) of <0.7, and FEV1 reversibility of 10% or more after inhalation of 400 lg salbutamol or 1 mg terbutaline sulphate. They should have been current or ex-smokers (smoking history of at least 10 pack-years) and be on maintenance therapy with LABA and/or longacting muscarinic antagonists (LAMA), ICS/LABA or ICS plus LAMA combination. Patients with abnormal chest radiography, clinical chemistry, haematology, urine analysis, physical or cardiovascular findings, or patients who had any significant disease or disorder which could put the patient at increased risk if participating in the study, were excluded. Patients requiring oxygen therapy or who had had an exacerbation (defined as use of oral or parenteral glucocorticoids or antibiotics, or hospitalization due to COPD) within 6 weeks of entering the run-in period were also excluded from participation in the study.
Study outline. The study comprised four periods: (i) screening period between enrolment and confirmation of eligibility (when an informed consent was to be obtained); (ii) 4-week run-in period after the screening visit until randomization; (iii) 12-week treatment period; and (iv) 1-week follow-up.
Patients who met all the inclusion criteria and had signed an informed consent form entered the run-in period where 9 lg inhaled formoterol bid was provided. Short-acting b 2 -adrenoceptor agonists (SABA) were the only allowed reliever therapy. After the run-in period, patients who fulfilled the randomization criteria were randomly assigned (in a ratio of 1:1:1) to a 12-week double-blind treatment with 9 lg inhaled formoterol bid plus any one of the following investigational treatments. AZD5423 via Turbuhaler (batch nos 12-000289AZ and 12-000398AZ, AstraZeneca) -180 lg targeted delivered dose (translating to 75 lg targeted lung deposited dose) once daily for 4 weeks followed by 800 lg targeted delivered dose (300 lg targeted lung deposited dose) once daily in the morning (with placebo in the evening) for 8 weeks. Budesonide via Turbuhaler (batch no 11-003373AZ, Astra Zeneca) -640 lg delivered dose twice daily Placebo via Turbuhaler (batch no 11-003374AZ, AstraZeneca) -delivered twice daily During run-in and treatment, rescue treatment with inhaled SABA, mucolytics and expectorants was allowed. During treatment, oral, inhaled or parenteral corticosteroids, and/or antibiotics were allowed as judged by the investigator. Treatment visits at the clinic were to take place at weeks 2, 4, 8, 10 and 12 after randomization. Patients were asked to fill in an eDiary from screening visit (at start of run-in) until week 12 of treatment, and then to come back 1 week after the last treatment visit for follow-up.
The study was approved by the local research ethics board at each participating centre, and signed informed consent was obtained from all study participants before any study-related procedures took place.
Outcome measures.
Clinic assessment of lung function and health status. The primary efficacy outcome measure was the change in pre-dose FEV1 from baseline (at randomization) towards end of treatment (FEV1 average over weeks 8, 10 and 12) , as assessed by spirometry. Secondary outcome variables were pre-dosing and after dosing clinic spirometry measures other than pre-dose FEV1 average of 8-12 weeks (i.e. predose FEV1 average at 0-4 weeks, pre-dose FVC and 15-30 min. after dosing FEV1 and FVC averages over 2-4 weeks (0-4 weeks after dosing clinic spirometry) and 8-12 weeks). Additional secondary variables were 0-4 and 8-12 weeks eDiary registrations of average of morning and evening spirometry and reliever use, symptoms and dyspnoea, and the St. George's Respiratory Questionnaire for COPD (SGRQ-C) [22] . Secondary outcome measures were assessed at each clinic visit.
eDiary assessments performed at home. Morning and evening FEV1 and peak expiratory flow (PEF) were self-assessed daily from start of runin and throughout treatment performed with a hand-held electronic spirometer. The COPD breathlessness, cough and sputum scale (composite BCSS) [23] was used to record symptoms. The total BCSS scale ranges from 0 to 12 wherein higher scores indicate greater symptom severity, and where a minimally important difference was defined as a change in total score of >0.3 units. Dyspnoea was assessed using the dyspnoea index -a multi-dimensional measure of functional impairment, magnitude of task and magnitude of effort in relation to activities of daily living [24] . The dyspnoea index was assessed at baseline (BDI) and during treatment (transitional dyspnoea index or TDI), where TDI expresses change from baseline. Daily recordings of reliever medication use (morning and evening) and night time awakenings (registered the morning after) were also entered into the eDiary.
Exacerbations. A COPD exacerbation was defined as 1 or more hospitalizations due to COPD, use of oral or parenteral corticosteroid, or use of oral or parenteral antibiotics. Number of exacerbations and time to first exacerbation were assessed.
Assessment of AZD5423 plasma concentration. Sparse plasma samples for determination of AZD5423 were collected in all randomized patients at week 4 and at week 12 at the following time-points: Pre-treatment, 5-20 min., and 30 min. to 1.5 hr. Exact sampling times were collected (sparse data set). Extensive 24-hr plasma samples for determination of AZD5423 (rich data set) were collected in a subgroup of patients at weeks 4 and 12. Samples were analysed for AZD5423 using a validated bioanalytical method, based on liquid chromatography and mass spectrometry (LC-MS/MS), with a lower limit of quantification of 10.0 pmol/L [25] . AUC 0-t , AUC 0-24 , C max and T max at steady-state was calculated using Phoenix Winnolin version 6.3 and summarized with descriptive statistics. Dose proportionality was assessed using predicted lung deposited doses, derived from in vitro measurements of the specific drug batches used in the trial and mathematical modelling for aerosol deposition in the human respiratory tract [26] .
Plasma cortisol. Morning plasma cortisol was assessed in all patients. In a patient subgroup (the same as for the assessment of the rich plasma AZD5423 data set), 24-hr plasma cortisol sampling was performed at weeks 0, 4 and 12. To evaluate the effect of AZD5423 on the hypothalamus pituitary adrenal (HPA) axis, the primary variable of interest was the AUC of 24-hr plasma cortisol levels. The plasma cortisol assay is described elsewhere [27] .
Assessment of other biomarkers. Biomarkers to explore local and systemic inflammation (high sensitivity C-reactive protein; surfactant protein-D; fibrinogen; and dehydroepiandrosterone sulphate) and bone turnover (osteocalcin) were assessed before and after 4 and 12 weeks of treatment. Biomarkers were analysed using established clinical assays.
Tolerability. Tolerability was assessed at each clinic visit by documenting adverse events (AEs), serious AEs (SAEs), laboratory safety data, urine analysis, ECG, vital signs (blood pressure and pulse rate) and physical examination.
Statistical approach and sample size. To assess the efficacy of AZD5423 with respect to the primary end-point, FEV1 change from baseline, analysis of covariance (ANCOVA) was used where treatment and country were included in the model as factors and baseline FEV1 was used as covariate. The same type of analysis was used for other end-points as well. For most end-points, data from an average of two or more weeks were used. All hypothesis testing was conducted using 2-sided tests at 5% significance level, with p-values ≤0.05 considered to be statistically significant.
A total of 315 patients were estimated to be needed to achieve 80% power for the primary comparison -change in average pre-bronchodilator FEV1 of AZD5423 versus placebo at weeks 8-12 -using a 2-sided test at the 5% significance level. This sample size, randomized in a 1:1:1 ratio, assumed a difference in FEV1 of 100 mL between AZD5423 and placebo, a S.D. of 250 mL, and a drop-out of 5% of patients. The S.D. assumption was based on earlier COPD studies [28, 29] .
The sample size estimation for the subgroup undergoing extensive 0-24-hr plasma cortisol sampling was based on showing superiority of AZD5423 versus budesonide using a 2-sided test at the 5% significance level. With an assumed cortisol suppression of 40% for budesonide versus placebo [30, 31] , a relative suppression of 29% versus AZD5423 and a coefficient of variation (CV) of 30%, 150 patients (50 per treatment group) were needed to show a statistically significant difference.
Results
The study was performed in accordance with the declaration of Helsinki and was consistent with the ICH/GCP guidelines, local regulatory and ethics requirements and the AstraZeneca policy on bioethics and human biological samples.
Patient flow.
A total of 482 patients with COPD were enrolled at 54 centres across eight countries, with first patient starting treatment in April 2012 and last patient completing the study in April 2013. Patient flow is summarized in fig. 1 Of the 353 patients randomized to receive treatment, 163 patients were part of the subgroup for the 24-hr plasma cortisol and 24-hr pharmacokinetic (PK) sampling. Baseline characteristics between treatment groups were well balanced with respect to age, disease severity and years since diagnosis (table 1) . At screening, pre-bronchodilator FEV1 was 52.2%, 50.5% and 50.2% predicted in the AZD5423, budesonide and placebo groups, respectively. Bronchodilator reversibility was 21.1%, 23.6% and 22.7%, respectively, in the three groups. There was a higher frequency of current smokers in the AZD5423 group (55% versus 41% and 48% for budesonide and placebo, respectively). Patient compliance was 89% in terms of study drug intake, and 90% in terms of e-Diary registrations.
Lung function.
Lung function data following treatment are shown in table 2. Pre-bronchodilator FEV1 and morning PEF during treatment are illustrated in figs 2 and 3, respectively. In the primary comparison, AZD5423 was not superior to placebo in average FEV1 at either 0-4 weeks (following 180 lg daily) or 8-12 weeks (following 800 lg daily). Overall, there were no statistically significant differences in any of the lung function parameters studied (FEV1, FVC or PEF) for either AZD5423 or budesonide (following 1280 lg daily) relative to placebo, nor was there any statistically significant difference between AZD5423 and budesonide ( 
Symptoms.
Response variables other than spirometry are presented in table 3. Overall, 20 exacerbations occurred during the study. There was no apparent difference between treatment groups in either time to first exacerbation or number of exacerbations between groups. There was no statistically significant difference in total daily use (morning and evening) of reliever medication after AZD5423 versus budesonide or placebo, or after budesonide versus placebo. There was a difference in favour of AZD5423 in evening use of reliever at 4 weeks (following 180 lg daily; 1.4 at baseline to 1.0 at 4 weeks, p = 0.04 versus placebo) and -borderline -at 12 weeks (following 800 lg daily) (1.4 at baseline to 1.0 at 12 weeks, p = 0.08 versus placebo). There was no statistically significant difference between groups in night-time awakenings or BCSS (composite or individual components) following 4 or 12 weeks treatment. Transitional dyspnoea index improved more in the budesonide group than in the AZD5423 and placebo groups (descriptive analysis: TDI was 0.41, 1.10 and 0.64, respectively for AZD5423, budesonide and placebo at 4 weeks, and 1.16, 1.54 and 0.69 at 12 weeks). There was no statistically significant difference between groups in SGRQ-C (total or component scores). Baseline total and component SGRQ-C scores were those expected from the population of patients with COPD participating in the trial.
Biomarkers.
Inflammatory, adrenal and bone biomarkers were assessed at baseline and at 4 and 12 weeks. Odds ratio (OR) plots are presented in fig. 4 Although occasional differences were found which were of statistical significance, only a few were considered to be clinically meaningful: budesonide suppressed DHEAs during treatment, while AZD5423 had a similar effect only at 12 weeks (following the high dose), and at 12 weeks budesonide but not AZD5423 affected osteocalcin. 24-hr plasma cortisol was followed in a subgroup of patients at baseline and at 4 and 12 weeks ( fig. 5A-C) . Odd ratios of 24-hr plasma cortisol ratios between treatments at 4 and 12 weeks are given in fig. 5D . There was no statistically significant reduction in 24-hr cortisol after AZD5423 versus placebo (OR 0.92, p = 0.27) at 4 weeks, but following the higher dose of AZD5423 at 12 weeks, 24-hr cortisol was significantly reduced (OR 0.84 versus placebo, p = 0.03). While AZD5423 did not affect 24-hr plasma cortisol versus budesonide at either 4 weeks (OR 1.14, p = 0.08) or 12 weeks (OR 1.14, p = 0.11), budesonide significantly suppressed 24-hr cortisol versus placebo at both 4 weeks (OR 0.8, p = 0.004), and at 12 weeks (OR 0.74, p < 0.001). There were no clinically relevant, nor statistically significant, reductions in mean morning plasma cortisol after either AZD5423 or budesonide ( fig. 5E) .
Overall, these biomarker findings suggest that both treatments were well tolerated, and that differences between AZD5423 and the reference GR agonist could not be distinguished. However, data suggest that inhaled budesonide may be somewhat more prone to exert systemic effects than AZD5423 at the doses tested.
Pharmacokinetics.
Plasma concentration versus time profiles of AZD5423 over 24 hr were followed at 4 weeks (low dose) and 12 weeks (high dose) in a subgroup of patients (rich data set, fig. 6 ). The plasma profiles of inhaled AZD5423 were characterized by rapid absorption followed by rapid distribution and a multi-exponential decline. Pharmacokinetic data are compiled in table 4. Delivered and lung-deposited doses are also provided in table 4. Fine particle dose was attained using a cascade impactor connected to a mouth cast and the recommended inhalation airflow, and was assumed to be equal to the lung deposited dose in the study. The estimated lungdeposited doses were used for the dose proportionality estimation. The sparse sampling attained in the whole group of randomized patients exposed to AZD5423 coincided well with the data at corresponding time-points in the subgroup undergoing rich plasma PK sampling. Exposure increased with dose, and there was no suggestion that AZD5423 does not display dose proportional PK in the dose range investigated.
Safety.
Vital signs, physical examination, ECG, haematology and urine analysis and AE were recorded at all clinic visits. Overall, there were no clinically relevant patterns in laboratory safety test results, ECG or vital signs during the study, and no marked differences between the treatment groups. AEs were evenly distributed and there were few with severe intensity (table 5) . One death in the AZD5423 group (pneumonia) was considered by the principal investigator not to be causally related to treatment. No safety or tolerability concerns were identified in the study.
Discussion
The purpose of the present study was to gain an early understanding of the therapeutic potential of a novel non-steroidal GR modulator -AZD5423 -in patients with COPD. The results suggest that neither AZD5423, at doses which have shown to be efficacious in a model of allergen-induced asthma [20] , nor budesonide at double the approved dose for COPD, have any clinically meaningful efficacy in the patient population studied in regard to lung function or markers of inflammation.
Budesonide -a well-established and safe ICS for the treatment of COPD -at 1280 lg daily delivered dose was selected as reference treatment besides placebo. In large and well- Fig. 3 . Weekly means of morning PEF (eDiary data; Least square means and standard error) following treatment with AZD5423 (180 lg daily for 4 weeks followed by 800 lg daily for 8 weeks), budesonide (1280 lg daily) and placebo. Baseline defined as the last value prior to first dose of randomized treatment. 2 12 weeks accumulated no. 3 0-to 4-week average. 4 Breathlessness, cough and sputum score. 5 Transitional dyspnoea index expressed as means (S.D.) 6 St George's Respiratory Questionnaire for COPD. 7 Patient no. *p ≤ 0.05.
controlled trials in moderate-to-severe COPD, budesonide plus formoterol have shown to reduce exacerbation risk and improve lung function versus the individual mono-components [8, [31] [32] [33] [34] . Also, in a number of smaller short-term COPD trials, budesonide has significantly improved lung function, and then specifically in patients responsive to b2-adrenoceptor agonists [35, 36] . In the current study, a budesonide dose double the approved was chosen to maximize any ICS efficacy signal in the population studied. A bronchodilator reversibility criterion (10%) was included to enrich the trial with patients expected to respond to ICS [35, 36] . Inhaled formoterol 9 lg (delivered dose) bid was introduced at run-in and then used throughout the treatment (together with SABA prn), as LABA is well-established in combination with anti-inflammatory ICS as the most efficacious maintenance treatment of COPD [5] .
Patient groups were well-balanced and patient drug compliance was high. The AZD5423 group had a higher ratio of current smokers than the other two groups. It has been suggested that smoking may reduce any potential beneficial effect of ICS [37] . However, in the budesonide group, the fraction of current smokers was lower than in the placebo group, but budesonide still showed lack of efficacy. Hence, this demographic imbalance should have had little impact on the trial outcome. Lung function was selected as primary efficacy readout, as it was assumed to be an appropriate surrogate marker of COPD inflammation and acute exacerbation risk -two primary targets of ICS treatment [7] . Lung function has shown to be improved within 12 weeks of ICS treatment, as opposed to other measures of airway inflammation [35, [37] [38] [39] . Still, using lung function as a surrogate marker for reduced exacerbation risk is controversial, as several studies have been unable to show a clear benefit of ICS in certain COPD patient groups [10] . However, to study the primary clinical end-point for an anti-inflammatory drug in COPD -exacerbation riska trial of much larger size and longer duration would have been required. For an explorative compound in early clinical development, this approach was considered not feasible. Dose selection of AZD5423 was based on the fine particle (lung-deposited) doses used in the allergen challenge asthma trial [20] , although different formulations were used (nebulizer suspension in the allergen challenge study and Turbuhaler in the current study). Lung-deposited doses were derived from pre-clinical potency estimates and systemic biomarker findings in the multiple ascending dose trial in healthy individuals. The staggered dose regimen (180 lg daily for 4 weeks followed by 800 lg daily for 8 weeks) successfully provided an early indication of dose proportionality in pharmacokinetics and pharmacodynamics in patients with COPD, while assuming little risk of compromised lung function improvement versus a trial design where the high dose would be given for the full 12 weeks of the trial.
Geometric mean ratio 95% CI
Although some ICS are used once daily in asthma, among them budesonide [40] , only fluticasone furoate has shown to be effective in a COPD setting when dosed once daily [9] . There is, however, little reason to believe that the once-daily regimen of AZD5423 would have limited the chance of identifying an efficacy signal, as budesonide, given twice daily at a Fig. 6 . Plasma concentration of AZD5423 versus time at 4 and 12 weeks. Geometric means and 95% CI following repeated inhaled doses of 180 lg at week 4 (n = 47) and of 800 lg at week 12 (n = 51). Table 4 . Pharmacokinetic data of AZD5423 at steady-state (≥4-week treatment -rich and sparse data sets). Geometric means (standard deviation). Number in superscript denotes number of patients in each data set. Targeted dose was attained from historic data and estimated doses from the actual batches used in the study. high daily dose, also showed a lack of effect. Indeed, pre-clinical and clinical properties of AZD5423 do suggest once-daily anti-inflammatory efficacy. In addition, the high AZD5423 dose used -4 times the lowest effective lung dose in the asthma trial [20] -would circumvent any potential risk of efficacy drop-out during the dosing interval.
In the current trial, AZD5423 was provided as a powder aerosol and delivered via Turbuhaler. Previous clinical safety and efficacy studies with this compound used nebulizer suspensions [20, 27] . However, in a PK trial in healthy individuals, the Turbuhaler powder formulation of AZD5423 performed as expected [25] . Also in the present study, the plasma concentration data of AZD5423 versus time were similar to the dose-normalized plasma concentrations of AZD5423 found in healthy individuals when the PK of AZD5423 was studied over a wide dose range [27] . In addition, plasma cortisol suppression was what would have been expected from the previous tolerability trial: In the multiple ascending dose study in healthy individuals, plasma cortisol was significantly suppressed by AZD5423 versus placebo (29% suppression) at 375 lg lung-deposited dose via nebulizer, while no suppression could be distinguished at doses below 300 lg [27] . In the present study, a suppression of 16% was observed at 12 weeks following 404 lg predicted lung-deposited dose of AZD5423 via Turbuhaler (corresponding to 800 lg daily delivered dose). This suggests a slightly less HPA effect than in the healthy volunteer study, but still in line with other findings where plasma cortisol suppression following ICS was less apparent in COPD and asthma patients than in healthy individuals [41, 42] . Finally, the effect on DHEAs -another marker of systemic HPA effect -was statistically significant for both AZD5423 and budesonide, while budesonide but not AZD5423, affected osteocalcin -a sensitive biomarker of bone formation. Hence, overall, the patient drug compliance, PK and systemic biomarker data including 24-hr plasma cortisol clearly suggest that patients have been exposed to study drugs and have indeed taken their medication as prescribed.
Chronic obstructive pulmonary disease is a complex disease, where the pathogenic mechanisms are not fully understood. While ICS has a broad spectrum of anti-inflammatory action and an established place in COPD therapy, it may be na€ ıve to expect equal or better efficacy of a selective GR modulator with a potentially more selective anti-inflammatory action than ICS. However, pre-clinical models have not suggested that the spectrum of beneficial anti-inflammatory effects of AZD5423 should be compromised relative to traditional ICS [18] . On the contrary, both pre-clinical and clinical studies have shown that the improved ratio between beneficial and systemic effects of AZD5423 would allow for more aggressive dosing with maintained safety versus traditional ICS, and greater anti-inflammatory efficacy as a potential outcome.
Global Initiative for Chronic Obstructive Lung Disease guidelines recommend ICS to be used in COPD patients with severe or very severe airflow limitation with frequent exacerbations that are not adequately controlled by long-acting bronchodilators [1] . It has been suggested that responders to ICS comprises only 15-20% of patients with a confirmed COPD diagnosis [7] . Accordingly, it is imperative to find the right population, when efficacy and potency of GR agonists are to be studied in COPD. Neither prior responsiveness to steroids nor bronchial hyperreactivity (a cardinal feature of ICSresponsive asthma) was assessed in the trial. However, none of these features have been demonstrated to be predictors of ICS response in COPD [4, 6] . Most patients in the trial were non-atopics (64-69% in the individual treatment groups) as defined by a negative phadiatop test, and most had a longterm history of smoking (average of more than 30 pack-years in each treatment group). This may have limited the number of ICS responding patients in the current trial.
Virtually all patients in the current trial responded to SABA, with a reversibility of more than 20% at screening. There is a belief that patients reversible to b 2 -adrenoceptor agonists are more prone to respond to ICS [32] , but systematic reviews have failed to confirm this [5, 6] . On the contrary, several studies exploring ICS responsiveness identified patients with no or little reversibility to salbutamol to be responsive to ICS [38, 43] . These and other studies have suggested steroid-na€ ıve or current non-users of ICS to be those most ICS-responsive of patients with COPD [44] . In our study, relatively many of the enrolled patients (55-62% of patients in individual treatment groups) used either ICS or ICS/LABA prior to run-in. Overall, the detection of a clinically relevant response to ICS is complex and nothing which can be taken for granted in any well-defined group of patients with COPD. If another COPD phenotype had been selected for the present trial -for example, those with little history of ICS use and/or those of a more distinct exacerbation-prone phenotype -a different outcome may potentially have resulted.
In conclusion, AZD5423 inhaled once daily via Turbuhaler was not effective in the COPD population as measured in the present study using lung function as primary readout and the doses studied, while showing plasma exposure and systemic effects of a magnitude expected from previous trials in healthy individuals and patients with asthma (where local anti-inflammatory effects of AZD5423 have previously been demonstrated). However, the reference treatment -twice-daily inhaled budesonide at double the approved dose -also showed lack of therapeutic efficacy while providing evidence of systemic effects. Hence, it cannot be ruled out that AZD5423, like budesonide, is efficacious in asthma and/or in a different (ICS-responsive) COPD subpopulation, or if using a different dosing regimen (e.g. a higher dose given in the evening) or a different study design (e.g. longer treatment duration and a different efficacy readout).
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